Intracellular biology of Alzheimer's disease amyloid beta peptide
T Hartmann - European archives of psychiatry and clinical …, 1999 - Springer
T Hartmann
European archives of psychiatry and clinical neuroscience, 1999•SpringerStrong evidence links excess production of a small peptide and the pathogenesis of
Alzheimer's disease (AD). Originally this peptide, beta-amyloid 42 (Aβ42), was assumed to
be released by a pathogenic event; it is now well established that Aβ42 is released from
cells during normal cellular metabolism of the Alzheimer amyloid precursor protein.
Recently, in a series of surprising reports it was discovered that Aβ42 is produced
intracellularly, and what might have been regarded first as a strange abnormality of a few …
Alzheimer's disease (AD). Originally this peptide, beta-amyloid 42 (Aβ42), was assumed to
be released by a pathogenic event; it is now well established that Aβ42 is released from
cells during normal cellular metabolism of the Alzheimer amyloid precursor protein.
Recently, in a series of surprising reports it was discovered that Aβ42 is produced
intracellularly, and what might have been regarded first as a strange abnormality of a few …
Abstract
Strong evidence links excess production of a small peptide and the pathogenesis of Alzheimer’s disease (AD). Originally this peptide, beta-amyloid 42 (Aβ42), was assumed to be released by a pathogenic event; it is now well established that Aβ42 is released from cells during normal cellular metabolism of the Alzheimer amyloid precursor protein. Recently, in a series of surprising reports it was discovered that Aβ42 is produced intracellularly, and what might have been regarded first as a strange abnormality of a few selected cell lines has now been recognized as an important cellular pathway for Aβ production. Moreover, the differences between secretory and intracellular Aβ production might hold the clues for brain specificity and cellular mechanisms of AD pathogenesis.
Springer
